Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
957 USD | +2.07% | +8.36% | +8.96% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The firm trades with high earnings multiples: 27.2 times its 2024 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.96% | 101B | B+ | ||
-1.43% | 103B | B+ | ||
+4.40% | 23.07B | B | ||
-12.15% | 22.23B | B+ | ||
-4.36% | 18.05B | A- | ||
-39.98% | 17.18B | A- | ||
-10.04% | 16.94B | B | ||
+6.79% | 14.07B | C+ | ||
+38.61% | 12.35B | C+ | ||
-24.53% | 8.36B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- REGN Stock
- Ratings Regeneron Pharmaceuticals, Inc.